Immunovaccine Inc

Presenter: Marc Mansour, Vice President R&D

Company Profile

Immunovaccine Inc. (TSX-V:IMV) has a patented vaccine delivery system that enhances both therapeutic cancer and infectious disease vaccines. The company's market cap is $60M and growing. Immunovaccine is at an exciting stage of development, having FDA clearance to take a therapeutic cancer vaccine into a Phase 1 clinical trial . The company also has early revenues through licensing its vaccine delivery system to Pfizer Animal Health. Immunovaccine would like to present an overview of its novel vaccine delivery platform and discuss the company's aggressive growth strategy.

Company Strategy

Immunovaccine Inc. develops premium vaccines, using its patented delivery platform "DepoVax" - for therapeutic cancer and infectious diseases

They have a three pronged business strategy:
(1) Generate animal health revenues to fund the human health business
(2) Partner out DepoVax to deliver other company's vaccines better than they can
(3) Develop the company's own vaccine products

Intellectual Property

Immunovacine owns a strong intellectual property portfolio for its platform technology, including 18 granted patents and applications in Canada, US, Europe, Australia and Japan. US Patent 6,793,923 (issued in 2004) contains very broad claims to Immunovaccine's platform, covering "any antigen, any adjuvant in any liposome and any oil". The platform name is protected by trademark in the US and Europe. Immunovaccine has also filed additional patent applications to protect DepoVax formulations as well as delivery of oligonucleotides and others. Immunovaccine will continue to follow the strategy of filing composition of matter and use patents for immunotherapeutic.

Programs

Immuvaccine has developed an optimized vaccine platform, trade-named DepoVax. The DepoVax platform is highly efficacious, and has the ability to raise strong cellular and humoral immune responses to a variety of antigens equal to or better than the original vaccine.

In addition to several research collaborations advancing a range of infectious disease and cancer indications, Immunovaccine has two vaccines in its pipeline.

The first is DPX-Pseudomonas. This is a Pseudomonas aeruginosa vaccine at a preclinical stage being designed to protect against hospital acquired infections in immune compromised patients.

The second is DPX-0907, Immunovaccine's lead product. DPX-0907 is a therapeutic cancer vaccine that is in Phase 1 clinical trials. DPX-0907 targets breast, ovarian and prostate cancers.

Investors

Public company.

Management Team

Dr. Randal Chase - President & CEO
Gary Dodge - Chief Financial Officer
Brian Lowe - Vice President
Dr. Marc Mansour - Vice President R&D

Presenter Bio

With over 17 years of local and international experience in corporate finance, reporting, mergers and acquisitions, Mr. Dodge brings extensive experience to Immunovaccine's business planning and operations. Mr. Dodge was, most recently, Chief Financial Officer of SolutionInc Technologies limited, a TSX Venture reporting company. During his 14 years with PricewaterhouseCoopers LLP in Boston, MA, Johannesburg, South Africa, and Calgary, Alberta, Mr. Dodge was principally focused on providing mergers and acquisitions advisory, auditing, and consulting services to public and private companies across numerous industries, including biotech.

Contact

Immunovaccine Inc
1819 Granville Street, Suite 303
Halifax
Nova Scotia, Canada
B3J 3R1

ph: +1 902 492 1819
fx: +1 902 492 0888

www.imvaccine.com
mmansour@imvaccine.com

April 6-8, 2010